Concepedia

Thomas Bohnacker

TB

Statistics

Publications

17

Citations

1.2K

H-Index

17

Active since

2009

Affiliations

University of Basel(Current)

PIQUR Therapeutics (Switzerland)

MRC Laboratory of Molecular Biology

University of Victoria

University of Turin

Thomas Bohnacker is an author at University of Basel specializing in pharmacology, life sciences, and pi3k signaling.

ORCID

Publications per year

2009–2020

17

Publications

17

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović et al. · Journal of Medicinal Chemistry · 2017 · 134 citations · Full text

, , +14

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

Romina Marone, Dominik Erhart, Ann C. Mertz et al. · Molecular Cancer Research · 2009 · 124 citations

, , +16

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

Thomas Bohnacker, A.E. Prota, Florent Beaufils et al. · Nature Communications · 2017 · 116 citations · Full text

, , +13

Ras is an indispensable coregulator of the class I <sub>B</sub> phosphoinositide 3-kinase p87/p110γ

Barbara Kurig, Aliaksei Shymanets, Thomas Bohnacker et al. · Proceedings of the National Academy of Sciences · 2009 · 95 citations

, , +16

PI3Kγ Adaptor Subunits Define Coupling to Degranulation and Cell Motility by Distinct PtdIns(3,4,5)P <sub>3</sub> Pools in Mast Cells

Thomas Bohnacker, Romina Marone, Emilie Collmann et al. · Science Signaling · 2009 · 91 citations

, , +16

1–5 of 17